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Abstract
Purpose Extension of adjuvant endocrine therapy (ET) reduces the risk of recurrence in women diagnosed with ER-positive 
breast cancers, but a significant benefit is unlikely to happen to all individual patients. This study is aimed at evaluating the 
ability of different clinical late distant recurrence (LDR) risk stratification methods and in particular the clinical treatment 
score at 5 years (CTS5) to predict the response to extended adjuvant ET.
Methods 783 patients diagnosed with ER+ BC between 1988 and 2014 at Umberto I Hospital of Turin, of which 180 
received an extended adjuvant ET, were retrospectively selected. They were stratified according to pT, pN, disease stage, 
tumor grade, Ki67 level, progesterone receptor status and CTS5. The primary endpoint was LDR rate. LDR rates according 
to ET duration were confronted in each subgroup.
Result The median duration of extended ET was 7 years (6–10). Median follow-up from diagnosis was 9 years (6–26). Ret-
rospective risk stratification according to tumor size, nodal status, disease stage, tumor grade, Ki67 level, and progesterone 
receptor status did not appear to be able to predict the response to extended ET. In the CTS5 high-risk subgroup instead, the 
risk of developing an LDR was significantly lower in the patients who underwent extended ET compared to standard ET (HR 
0.37, 95% CI 0.15–0.91), while no significant benefit was demonstrated for low and intermediate-risk patients.
Conclusions Risk stratification according to CTS5 appeared to be predictive of the response to extended endocrine therapy 
in our population of real-life pre and postmenopausal patients.
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Introduction
Breast cancer is the most frequent neoplasia in women 
worldwide, and about 80% of new diagnoses are estrogen 
receptor-positive (ER+) tumors [1]. With current surgical 
and medical treatment, the results both in terms of disease 
recurrence and short-term survival for early ER+ breast can-
cer patients are excellent [2]. 5 years of adjuvant endocrine 
therapy (ET) reduce mortality (by 30% with five years of 
Tamoxifen and 40% with an aromatase inhibitor (AI) in post-
menopausal women) [3] and hence represent the gold stand-
ard treatment for these patients [4]. Nevertheless, up to 50% 
of distant recurrences (DR) show up after the completion of 
adjuvant endocrine therapy. Numerous studies on extended 
ET (e-ET) have shown a significant improvement in disease 
outcomes, but their results are hardly applicable to the cur-
rent clinical scenario. In postmenopausal women, extended 
therapy appears to be most beneficial in patients treated with 
Tamoxifen for 5 years who either continue Tamoxifen or 
switch to an AI-based regimen. Such schedules have now 
been long abandoned in favor of upfront AI therapies that 
have already shown superiority over Tamoxifen. On the con-
trary, the benefits of extending a 5-year course of adjuvant 
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AI appear to be less substantial, except for specific sub-
groups of patients at higher risk of recurrence. For premeno-
pausal women instead, data on extended therapy is limited 
and will not be applicable in the near future since the SOFT 
[4] and TEXT [5] trials have now revolutionized the clinical 
practice. On these premises, the selection of the patients at 
higher recurrence risk deemed to get the most benefit from 
an extended endocrine therapy has now become a promi-
nent concern. Many molecular profiles have been tested 
and proved to provide prognostic information on LDR risk 
after five years of ET, even though they were created to be 
used at diagnosis [6]. Contrariwise, the Clinical Treatment 
Score at 5 years (CTS5), which integrates four clinicopatho-
logical variables, was specifically developed to estimate the 
LDR risk after five years of adjuvant endocrine therapy for 
ER+ breast cancer. It was created and validated on the ATAC 
and BIG 1–98 cohorts of postmenopausal patients [7] and 
its prognostic ability has now been externally confirmed on 
different cohorts of pre and postmenopausal patients [8–11]. 
Apart from the prognostic information, limited data is avail-
able on the ability of these tools to predict the response 
to the extended ET. In particular, only the Breast Cancer 
Index (BCI) was shown to be predictive of the response to 
extended ET [12, 13].
This study aimed at evaluating the ability of different risk 
stratification methods (tumor size, nodal involvement, stage 
of disease, tumor grade, Ki67 level, progesterone receptor 
status and CTS5) carried out retrospectively to predict the 
response to an extended ET in a sample of pre and post-
menopausal real-life patients.
Materials and methods
Between 1988 and 2014, 2806 patients were treated for 
breast cancer at Mauriziano Umberto I Hospital of Turin. 
They underwent surgery, chemotherapy, radiation therapy, 
and endocrine therapy according to the guidelines in force 
at the time.
From this data set, we selected only patients with invasive 
tumors, complete clinicopathological data, and full immu-
nohistochemical characterization. Tumors were considered 
estrogen receptor-positive when the staining involved > 1% 
of the specimen cancer cells. Endocrine therapy was pre-
scribed, according to the guidelines, to all patients with 
tumors fulfilling this criterion.
We retained for this analysis 783 ER-positive, HER2 neg-
ative patients after excluding 101 patients who experienced 
a disease recurrence during the first five years of ET and 
26 patients who experienced a late locoregional recurrence 
without evidence of distant disease. One-hundred-eighty 
patients of the 783 selected underwent an e-ET. The patient 
selection process is outlined in Fig. 9.
The 783 remaining patients that were included in the anal-
ysis underwent a retrospective LDR stratification according 
to tumor size, nodal status, stage of disease, tumor grade, 
Ki67 level, progesterone receptor status and CTS5. CTS5 
score was calculated applying the final validated formula:
Patients were categorized in three risk groups based 
on the score obtained: low- (CTS5 < 3.13), intermediate- 
(3.13–3.86), and high-risk (> 3.86).
In each subgroup of the different risk stratifications, the 
patients were further divided according to endocrine therapy 
duration: standard 5 years course or extended regimen.
Extended endocrine therapy prescription was not the 
standard clinical practice in the period considered. The 
prescription was made according to the evaluation of the 
clinician of individual risk factors and in agreement with 
patients, with duration to be determined on the patients’ tol-
erance to treatment.
The primary endpoint of this study was the late distant 
recurrence (LDR) rate.
Statistical analysis
Categorical variables were confronted using Chi-square 
test. Two-sided p values < 0.05 were considered statisti-
cally significant. Survival analysis was performed with the 
Kaplan Meier method; the differences between the curves 
were estimated with the log-rank test. Hazard ratios were 
obtained with the Cox regression model and reported at the 
95% confidence interval.
Results
Out of the 783 women enrolled for this analysis, 533 (68.1%) 
were postmenopausal and 250 (31.9%) premenopausal. 
Patients’ characteristics are shown in Table 1. Median fol-
low-up after standard 5 years of adjuvant ET was 4 years 
(range 1–21). The 42.9% of our patients had at least a five-
year follow up, 18.9% a 3–4-year follow-up, the 38.2% 2 
or less years of follow-up. An Aromatase Inhibitors-based 
endocrine therapy was given upfront to 379 (71.1%) post-
menopausal women, while Tamoxifen + Ovarian Func-
tion Suppression (OFS) was the preferred choice for pre-
menopausal women (161/250, 64.4%) (Table 2). Extended 
endocrine therapy was prescribed to 180 patients, 107/533 
CTS5 = 0.438 × nodes + 0.988
×
(
0.093 × size − 0.001 × size2
+0.375 × grade + 0.017 × age).
Breast Cancer 
1 3
(20.1%) postmenopausal and 73/250 (29.2%) premenopau-
sal. For these patients, the median total duration of endo-
crine therapy was 7 years (6–10). Out of the 73 premeno-
pausal patients who have prescribed an extended ET, 34 
(46.6%) switched from Tamoxifen ± OFS to an AI, while the 
remaining 39 (53.4%) continued Tamoxifen without OFS (15 
patients previously on Tamoxifen alone and 24 patients pre-
viously on OFS). Concerning postmenopausal patients, 83 
(77.6%) continued on the same AI administered during the 
previous five years while 20 (18.7%) switched from Tamox-
ifen to an AI. Only four postmenopausal patients continued 
Tamoxifen alone in the extended setting. 
Global LDR rate was 8%: 9% in the 5 years ET group and 
5% in the extended ET group (p = 0.08) (Table 1). Median 
follow-up among patients who experienced an LDR was 
similar in both groups (5y ET: 10 years [6–26], extended 
ET: 10 years [6–16]).
To identify the patients at higher risk of LDR, a retro-
spective stratification was carried out according to CTS5 
and other parameters commonly used in the clinical prac-
tice: tumor size (T1, T2, T3 or higher), nodal involvement 
(pN0, pN1, pN2-3), stage of the disease (Stages I, II, III), 
tumor grade (low, intermediate, high), Ki67 (low [< 20%], 
high [> 20%]), and progesterone receptor status (negative 
[< 1%], positive [> 1%]). The prescription of extended endo-
crine therapy was significantly associated to worse clinical 
and pathological features. We observed a higher prescrip-
tion rate in patients with larger tumors (38.5% of pT3–4 
vs 26.9% of pT2 vs 19.5% of pT1, p = 0.01), patients with 
greater nodal involvement (34.3% of pN2–3 vs 30.6% of pN1 
vs 16.9% of pN0, p < 0.001), patients with a higher clinical 
stage (35.3% of Stage III vs 25.9% of Stage II vs 15.5% 
of Stage I, p < 0.001), patients with higher Ki67 (33.2% of 
Ki67 > 20% vs 16.5% of Ki67 < 20%), and patients with 
higher histologic grade (32.6% of G3 vs 17.8% of G2 vs 
10.3% of G1, p < 0.001). Instead, PgR status did not appear 
to affect e-ET prescription rate (18.7% of PgR-negative vs 
23.4% PgR-positive patients, p = 0.39). After obtaining the 
CTS5 score for all patients, we observed that an extended 
ET was also prescribed in a significantly higher proportion 
to patients categorized as High-Risk (31.9% vs 14.9% low-
risk, p < 0.001). Details are shown in Table 3.
No significant difference in terms of LDR risk could 
be observed between patients undergoing standard versus 
extended ET when they were categorized according to tumor 
size (Fig. 1), nodal involvement (Fig. 2), stage of disease 
(Figs. 3, 4), tumor grade (Fig. 5), Ki67 level (Fig. 6) and 
progesterone receptor status (Fig. 7).
Table 1  Patients’ characteristics
5 years of ET Extended ET
Total 603 (77.0%) 180 (23.0%)
Menopausal Status
 Premenopausal 177 (70.8%) 73 (29.2%)
 Postmenopausal 426 (79.9%) 107 (20.1%)
Median age
 Premenopausal 45 (26–54) 45 (27–54)
 Postmenopausal 67 (51–91) 64 (51–83)
Median ET duration
 Premenopausal 5 7 (6–10)
 Postmenopausal 5 7 (6–10)
Surgery
 BCS 425 (78.8%) 114 (21.2%)
 Mastectomy 178 (73.0%) 66 (27.0%)
LDR rate
 Total events 54 (9%) 9 (5%)
Table 2  Endocrine therapy
5 years of ET Extended ET
Premenopausal 73 (29.2%)
Tamoxifen 89 (35.6%) 39 (53.4%) [24+15]
Tamoxifen + OFS 161 (64.4%) 0
Aromatase Inhibitor 0 34 (46.6%)
Postmenopausal 107 (20.1%)






  103 (96,3%) [20 + 83]
*Arrows and numbers in bold: patients switching from one type of ET to the other, detail in text
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On the contrary, risk stratification according to CTS5 was 
shown to be predictive of the response to the extended endo-
crine therapy (Fig. 4). In particular, the risk of developing 
a late distant recurrence with extended endocrine therapy 
was significantly lower in patients categorized as high-risk 
(HR 0.37; 95% CI 0.15–0.91, p = 0.04) while no significant 
difference was outlined for low-risk patients (HR 0.03; 95% 
CI 0.00–103.29) and intermediate-risk patients (HR 1.09; 
95% CI 0.31–3.89).
Among patients categorized as high risk by CTS5, adju-
vant chemotherapy and radiotherapy were comparable both 
in the extended and in the standard ET groups. The majority 
of the patients prescribed an extended endocrine regimen 
underwent surgery after 2005 (Table 4), but no differences 
in terms of LDR risk could be outlined when compared 
to patients who underwent an extended ET after surgery 
performed before that year (HR 0.86, 95% CI 0.09–8.18) 
(Figs. 8, 9).
Discussion
A metanalysis published by Pan H. et al. including more 
than 60,000 women has shown that the risk of distant recur-
rence persists for at least 20 years from the diagnosis of 
an ER+ breast cancer [14]. There is now evidence that this 
risk can be reduced by extending the course of endocrine 
therapy, but a significant benefit is unlikely to happen to all 
individual patients.
Many studies have been conducted on this topic: eight 
RCTs involving more than 17,000 patients were recently 
included in a metanalysis by Corona et al., which confirmed 
the beneficial effect of the extended endocrine therapy on 
DFS but not on OS [15]. The protection offered by the 
extended endocrine therapy comes along with an increased 
incidence of therapy-related side effects: endometrial cancer 
and thromboembolic disease for Tamoxifen, cardiovascular 
events, and bone fractures for AIs [16]. These results raise 
several questions when it comes to recommending extended 
adjuvant endocrine therapy, such as those concerning patient 
selection, the agent of choice, and the duration of treatment.
Table 3  Extended ET according to pT, pN, Stage, ki67, PgR status 
and histologic tumor grade
5 years of ET Extended ET p value
Tumor size
 pT1 367 (80.5%) 89 (19.5%)
 pT2 220 (73.1%) 81 (26.9%) 0.01
 pT3-4 16 (61.5%) 10 (38.5%)
Positive nodes
 pN0 384 (83.1%) 78 (16.9%)  < 0.001
 pN1 154 (69.4%) 68 (30.6%)
 pN2–3 65 (65.7%) 34 (34.3%)
Stage  < 0.001
 Stage I 277 (84.5%) 51 (15.5%)
 Stage II 249 (74.1%) 87 (25.9%)
 Stage III 77 (64.7%) 42 (35.3%)
Ki67
 Low (< 20%) 400 (83.5%) 79 (16.5%)  < 0.001
 High (> 20%) 203 (66.8%) 101 (33.2%)
Histologic Grade
 G1 113 (89.7%) 13 (10.3%)
 G2 263 (82.2%) 57 (17.8%)  < 0.001
 G3 227 (67.4%) 110 (32.6%)
PgR status
 Negative (< 1%) 61 (81.3%) 14 (18.7%) 0.390
 Positive (> 1%) 542 (76.6%) 166 (23.4%)
CTS5
 Low risk 240 (85.1%) 42 (14.9%)
 Intermediate risk 179 (77.5%) 52 (22.5%)  < 0.001
 High risk 184 (68.1%) 86 (31.9%)
Fig. 1  LDR risk according to ET duration and tumor size
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Several multigene assays have been proven to provide 
prognostic information on the risk of LDR. A recently 
published pan-genomic analysis by the TransATAC study 
group compared the performance of six prognostic signa-
tures: CTS, IHC4, BCI prognostic score, Oncotype Dx, 
Prosigna, and EndoPredict. While all tools were able to 
provide prognostic information on the risk of early recur-
rence, only the BCI score, Prosigna, and EndoPredict 
demonstrated a significant ability to stratify patients for 
LDR risk, above and beyond clinical parameters [17]. The 
Fig. 2  LDR risk according to ET duration and nodal status
Fig. 3  LDR risk according to ET duration and stage of disease
Fig. 4  LDR risk according to ET duration and CTS5
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prognostic performance was weaker among patients with 
nodal involvement, once more underlying the importance 
of this clinical variable also in the long term.
So far, little is known about the magnitude of the benefit 
associated with the extended endocrine treatment according 
to the risk stratification carried out with the prognostic tools.
Historically, the decision to propose an extended endo-
crine regimen was based on the only two clinical variables 
shown to be independently associated with the risk of late 
recurrence: tumor size and lymph node burden [18]. More 
recently, an algorithm integrating four clinicopathological 
variables, the Clinical Treatment Score at 5 years (CTS5), 
Fig. 5  LDR risk according to ET duration and tumor grade
Fig. 6  LDR risk according to 
ET duration and Ki67
Fig. 7  LDR risk according to 
ET duration and PgR status
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was shown to be prognostic for late distant recurrence, thus 
providing useful information to help to tailor the prescrip-
tion of extended ET. This study was aimed at investigating 
whether the CTS5-based risk stratification could be helpful in 
choosing patients more likely to benefit from extended endo-
crine therapy. The analysis was conducted on a retrospective 
cohort of 783 patients, of which 180 were prescribed extended 
endocrine therapy. We found that neither tumor size nor nodal 
involvement, stage of the disease, tumor grade, Ki67 level, 
and progesterone receptor status could individually predict the 
response to such treatment. On the contrary, the risk stratifi-
cation according to CTS5-based showed a significant benefit 
of the extended endocrine therapy in high-risk patients with 
a 60% reduction in the risk of developing an LDR. This sug-
gests that the CTS5 can help in selecting the patients more 
likely to profit from the treatment. No benefit from extended 
ET administration has been observed in low and intermediate-
risk patients. It is to be noted that this result was obtained 
with a median duration of extended endocrine therapy of only 
7 years, while the standard consensus considers 10 years of 
endocrine therapy the ideal objective [19]. It has recently been 
observed that recent advantages in diagnostics and treatment 
could have concurred to the better outcomes of the patients 
treated with extended endocrine therapy [20]; however, we 
did not observe different LDR risks confronting patients who 
underwent an extended endocrine therapy after surgery per-
formed before versus after 2005. To our knowledge, this is the 
first study to evaluate the predictive ability of the CTS5. Only 
two other prospective-retrospective studies, both involving 
a component of Breast Cancer Index prognostic score (BCI 
H/I), have conducted a similar analysis. BCI (H/I) predictive 
ability was initially demonstrated in the NCIC-CTG MA.17 
RCT cohort (N = 249, 60% N +). Patients categorized as 
BCI (H/I)-High had a significantly improved outcome with 
extended letrozole treatment versus placebo: a 67% reduction 
in risk of recurrence (OR 0.35; 95% CI 0.16–0.75; p = 0.007), 
while patients with BCI (H/I)-low did not have a statistically 
significant decrease in late recurrence when treated with 
extended endocrine therapy (OR 0.68; 95% CI 0.31–1.52; 
p = 0.35). More recently, Bartlett and Sgroi tested the BCI 
prognostic index on 583 node-positive aTTom patients. 
They found a significant benefit from extended tamoxifen 
for patients classified as BCI (H/I)-High (HR 0.35; 95% CI 
0.15–0.86): The risk of recurrence was 27.0% and 37.2% for 
patients treated with 10- and 5-year tamoxifen, respectively, 
demonstrating a significant absolute 10.2% reduction of the 
risk of recurrence. In contrast, there was no significant benefit 
from an additional 5 years of tamoxifen in patients classified 
as BCI (H/I)-Low (HR 1.07; 95% CI 0.69–1.65). As described 
by Simon et al., level 1B classification for the clinical utility 
of a biomarker requires reproducibility of the results in at least 
two independents prospective–retrospective studies. BCI (H/I) 
can thus be considered a biomarker of response to extended 
endocrine therapy. Despite these encouraging results, the rou-
tine use of such assays is limited by availability and prohibi-
tive costs. They are not yet recommended for guiding therapy 
of ER + BC beyond 5 years from diagnosis [21, 22].
The results of our study suggest that also CTS5 can pre-
dict the response to extended endocrine therapy and should 
hence be taken into account in settings with difficult access 
to genomic signatures.
Limitations of this study are its pure retrospective 
design, the small number of patients prescribed the 
extended endocrine therapy, and the relatively short 
median follow-up that could have missed some LDR 
which are yet to develop. Moreover, the prescription of an 
extended endocrine regimen was based on the clinicians’ 
choice after the assessment of the risk factors taken singu-
larly, since no integration tool was available in the period 
considered. Hence, to correctly assess the predictive abil-
ity of CTS5, we recommend testing the score on a wider 
cohort until a prospective analysis can be carried out. The 
point of strength is the inclusion of pre and postmeno-
pausal patients, the majority of whom have been treated 
Table 4  CTS5 high risk patients
5 years of ET Extended ET p value
Chemotherapy
 Yes 141 (65.9%) 73 (34.1%) 0.14
 No 43 (76.8%) 13 (23.2%)
Radiotherapy
 Yes 134 (66.7%) 67 (33.3%) 0.45
 No 50 (72.5%) 19 (27.5%)
Timeframe
 ≤ 2005 87 (84.5%) 16 (15.5%)  < 0.001
 ≥ 2006 97 (58.1%) 70 (41.9%)
Fig. 8  LDR risk for CTS5 high-risk patients who underwent extended 
ET according to time of surgery
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Fig. 9  Patients selection process
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according to current guidelines, an aspect that enhances 
the applicability of the results of this study to everyday 
clinical practice.
Conclusions
Retrospective risk stratification according to CTS5 appeared 
to be predictive of the response to extended endocrine ther-
apy in our population of real-life pre and postmenopausal 
patients. Our results suggest its use in the clinical practice to 
better tailor the prescription of the extended adjuvant endo-
crine regimen.
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